Search results
Showing 1006 to 1020 of 8241 results
Evidence-based recommendations on pembrolizumab (Keytruda) for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults.
NICE is unable to make a recommendation on ibrutinib (Imbruvica) with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma in adults because Janssen did not provide an evidence submission.
Show all sections
Sections for TA702
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705)
Evidence-based recommendations on atezolizumab (Tecentriq) for treating advanced non-small-cell lung cancer in adults.
Ozanimod for treating relapsing–remitting multiple sclerosis (TA706)
Evidence-based recommendations on ozanimod (Zeposia) for treating relapsing–remitting multiple sclerosis in adults with clinical or imaging features of active disease.
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (TA695)
Evidence-based recommendations on carfilzomib (Kyprolis) with dexamethasone and lenalidomide (Revlimid) for previously treated multiple myeloma in adults.
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (TA698)
Evidence-based recommendations on ravulizumab (Ultomiris) for treating paroxysmal nocturnal haemoglobinuria in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy in adults.
Avelumab for treating metastatic Merkel cell carcinoma (TA517)
Evidence-based recommendations on avelumab (Bavencio) for metastatic Merkel cell carcinoma in adults.
Evidence-based recommendations on pemigatinib (Pemaryze) for relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.
Bimekizumab for treating moderate to severe plaque psoriasis (TA723)
Evidence-based recommendations on bimekizumab (Bimzelx) for treating moderate to severe plaque psoriasis in adults.
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) and chemotherapy for untreated metastatic non-small-cell lung cancer.
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer.
Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people aged 3 and older who have had a stem cell transplant or at least 2 previous therapies.
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (TA778)
Evidence-based recommendations on pegcetacoplan (Aspaveli) for treating paroxysmal nocturnal haemoglobinuria in adults who have anaemia after at least 3 months of treatment with a C5 inhibitor.
Secukinumab for treating non-radiographic axial spondyloarthritis (TA719)
Evidence-based recommendations on secukinumab (Cosentyx) for treating non-radiographic axial spondyloarthritis in adults.